PainReform Ltd. (PRFX)
USD 2.02
(1.51%)
USD 2.02
(1.51%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -9.58 Million USD | -8.06% |
| 2022 | -8.86 Million USD | -23.04% |
| 2021 | -7.2 Million USD | -331.36% |
| 2020 | -1.67 Million USD | -142.53% |
| 2019 | -689 Thousand USD | -37.8% |
| 2018 | -500 Thousand USD | 43.18% |
| 2017 | -880 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -5.56 Million USD | -56.14% |
| 2024 Q2 | -7.34 Million USD | -31.99% |
| 2023 Q2 | -2.25 Million USD | 6.79% |
| 2023 Q1 | -2.41 Million USD | 25.8% |
| 2023 FY | -9.58 Million USD | -8.06% |
| 2023 Q4 | -3.56 Million USD | -163.61% |
| 2023 Q3 | -1.35 Million USD | 39.96% |
| 2022 Q3 | -2.09 Million USD | -13.6% |
| 2022 Q2 | -1.84 Million USD | -10.35% |
| 2022 Q1 | -1.67 Million USD | 3.96% |
| 2022 FY | -8.86 Million USD | -23.04% |
| 2022 Q4 | -3.25 Million USD | -55.34% |
| 2021 FY | -7.2 Million USD | -331.36% |
| 2021 Q2 | -1.66 Million USD | 18.59% |
| 2021 Q3 | -1.76 Million USD | -6.51% |
| 2021 Q4 | -1.74 Million USD | 1.53% |
| 2021 Q1 | -2.03 Million USD | -195.08% |
| 2020 FY | -1.67 Million USD | -142.53% |
| 2020 Q4 | -691 Thousand USD | 1.29% |
| 2020 Q1 | -132 Thousand USD | 41.07% |
| 2020 Q2 | -148 Thousand USD | -12.12% |
| 2020 Q3 | -700 Thousand USD | -372.97% |
| 2019 Q3 | -224 Thousand USD | -85.89% |
| 2019 FY | -689 Thousand USD | -37.8% |
| 2019 Q1 | -120.5 Thousand USD | 0.82% |
| 2019 Q2 | -120.5 Thousand USD | 0.0% |
| 2019 Q4 | -224 Thousand USD | 0.0% |
| 2018 Q1 | -128.5 Thousand USD | 0.0% |
| 2018 Q2 | -128.5 Thousand USD | 0.0% |
| 2018 Q3 | -121.5 Thousand USD | 5.45% |
| 2018 FY | -500 Thousand USD | 43.18% |
| 2018 Q4 | -121.5 Thousand USD | 0.0% |
| 2017 FY | -880 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 105.74% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -281.041% |
| Embecta Corp. | 221.5 Million USD | 104.327% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 110.931% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -100.28% |
| SCYNEXIS, Inc. | 72.66 Million USD | 113.189% |
| Journey Medical Corporation | -2.07 Million USD | -362.325% |
| Safety Shot Inc | -12.18 Million USD | 21.34% |
| Alpha Teknova, Inc. | -35.56 Million USD | 73.051% |
| Bright Green Corporation | -8.89 Million USD | -7.79% |
| Procaps Group, S.A. | 38.97 Million USD | 124.591% |
| Alvotech | -354.86 Million USD | 97.299% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 120.404% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 36.538% |
| Cosmos Health Inc. | -21.83 Million USD | 56.1% |
| Dynavax Technologies Corporation | -37.02 Million USD | 74.117% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 93.839% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 93.987% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -100.28% |
| Theratechnologies Inc. | -10.62 Million USD | 9.815% |
| Harrow Health, Inc. | 580 Thousand USD | 1752.414% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -103.872% |
| Biofrontera Inc. | -22.67 Million USD | 57.737% |
| DURECT Corporation | -36.88 Million USD | 74.016% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -81.894% |
| Cronos Group Inc. | -81.37 Million USD | 88.222% |
| OptiNose, Inc. | -22.74 Million USD | 57.869% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 104.585% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 75.522% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 175.871% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 176.519% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | -121.017% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -54.311% |
| Radius Health, Inc. | -3.92 Million USD | -144.178% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -171.75% |
| ProPhase Labs, Inc. | -21.61 Million USD | 55.656% |
| Phibro Animal Health Corporation | 53.31 Million USD | 117.976% |
| Procaps Group S.A. | 52.32 Million USD | 118.317% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -12.449% |
| Viatris Inc. | 766.2 Million USD | 101.251% |
| Rockwell Medical, Inc. | -6.67 Million USD | -43.688% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -82.413% |
| SIGA Technologies, Inc. | 83.62 Million USD | 111.461% |
| Tilray Brands, Inc. | -174.74 Million USD | 94.515% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 202.711% |
| Shineco, Inc. | -17.06 Million USD | 43.841% |
| PetIQ, Inc. | 60.01 Million USD | 115.969% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -102.334% |
| Incannex Healthcare Limited | -30.04 Million USD | 68.097% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 103.82% |
| Alimera Sciences, Inc. | -1.47 Million USD | -551.53% |
| Silver Spike Investment Corp. | 7.34 Million USD | 230.57% |
| Assertio Holdings, Inc. | -243.53 Million USD | 96.065% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -62.651% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 29.619% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 38.54% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 52.2% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 93.047% |
| Hempacco Co., Inc. | -8.81 Million USD | -8.757% |
| Talphera, Inc. | -16.88 Million USD | 43.253% |
| Alvotech | -354.86 Million USD | 97.299% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 117.929% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 102.628% |
| Currenc Group, Inc. | -6.64 Million USD | -44.212% |
| Kamada Ltd. | 10.06 Million USD | 195.231% |
| Indivior PLC | -4 Million USD | -139.6% |
| Evoke Pharma, Inc. | -7.43 Million USD | -28.975% |
| Flora Growth Corp. | -50.35 Million USD | 80.967% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 52.2% |
| Evolus, Inc. | -49.23 Million USD | 80.533% |
| HUTCHMED (China) Limited | 18.37 Million USD | 152.158% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 104.865% |
| Akanda Corp. | -10.05 Million USD | 4.65% |